UCI Heath is at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Join UCI Health at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 to June 2 in Chicago, as we showcase how Orange County’s only academic health system is advancing the future of cancer care.
At the UCI Health Chao Family Comprehensive Cancer Center, a National Cancer Institute-designated comprehensive cancer center, we are bringing together nationally renowned physicians, scientists, and care teams to expand access to innovative therapies, multidisciplinary expertise and clinical trials for patients with complex and challenging cancers.
“ASCO remains an important forum for advancing precision oncology and sharing the insights that will shape more individualized cancer care,” said Richard Van Etten, MD, PhD, director of the UCI Health Chao Family Comprehensive Cancer Center. “At UCI Health, we are committed to translating those advances into stronger clinical trials access, multidisciplinary expertise, and leading-edge treatment options for patients across Orange County and beyond.”
Through translational research, precision medicine and advanced treatment approaches, UCI Health is helping move promising discoveries more quickly from bench to bedside.
Visit us on the exhibit floor at Booth No. 22132 to learn more about our expanding impact and career opportunities.
On Sunday, May 31 from 2-3 p.m., University of California Pancreatic Consortium leader and UCI Health medical oncologist Jennifer Valerin, MD, PhD will be available at the UCI Health booth to discuss newly reported daraxonrasib data, patient selection and what emerging RAS-directed therapies may mean for patients with metastatic pancreatic adenocarcinoma.
Also, we invite you to join UCI Health on Saturday, May 30 for a special Connect & Cure networking cocktail hour from 6-8 p.m. at Harray Caray’s Italian Steakhouse in Chicago, IL. Learn more and RSVP today.
UC Irvine faculty presentations and contributions at ASCO 2026
ORAL PRESENTATIONS
A phase 2 study of ipatasertib in combination with pembrolizumab for first-line treatment of recurrent or metastatic squamous cell cancer of the head and neck. Oral Abstract Session: Head and Neck Cancer. Abstract 6006. May 31, 2026; 10-10:12 a.m.
Emiltatug ledadotin (Emi-Le), a B7-H4-directed antibody-drug conjugate, in patients with aggressive adenoid cystic carcinoma: Phase 1 interim analysis. Clinical Science Symposium: Small Glands, Big Challenges: Novel Therapeutics in Salivary Gland Cancer. Abstract 6010. June 1, 2026; 8:24-8:36 a.m.
A phase 2 study of darolutamide plus leuprolide acetate in hormone-therapy naïve recurrent and/or metastatic androgen receptor-positive salivary gland cancer (ETCTN 10553). Clinical Science Symposium: Small Glands, Big Challenges: Novel Therapeutics in Salivary Gland Cancer. Abstract 6012. June 1, 2026; 8:48-9 a.m.
Enfortumab vedotin plus pembrolizumab vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma: 3.5-year follow-up and response analyses from the phase 3 EV-302 study. Oral Abstract Session: Genitourinary Cancer—Kidney and Bladder. Abstract 4507. May 29, 2026; 4:45-4:57 p.m.
Phase 1 study of NTX1088, a first-in-class anti-PVR monoclonal antibody, as monotherapy and combined with pembrolizumab, in patients with advanced solid malignancies. Rapid Oral Abstract Session: Developmental Therapeutics — Immunotherapy. Abstract 2518. May 30, 2026; 9-9:06 a.m.
POSTER PRESENTATIONS
A randomized phase II/III trial of intraperitoneal paclitaxel plus systemic treatment vs systemic treatment alone in gastric carcinomatosis: STOPGAP II—ECOG-ACRIN EA2234. Poster Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary. Abstract TPS4241. Poster Board 223a. May 30, 2026. 9 a.m.-12 p.m.
Phase 1 basket study of telisotuzumab adizutecan (Temab-A, ABBV-400), a c-Met protein-targeting antibody-drug conjugate: results from patients with head and neck squamous cell carcinoma (HNSCC). Poster Session: Head and Neck Cancer. Abstract 6027. Poster Board 484. May 30, 2026; 1:30-4:30 p.m.
Real-world treatment patterns and overall survival in patients with HER2-positive advanced or metastatic gastroesophageal adenocarcinomas in the United States. Poster Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary. Abstract 4053. Poster Board 36. May 30, 2026; 9 a.m.-12 p.m.
Real-world clinical outcomes by HER2 expression in locally advanced or metastatic urothelial carcinoma: results from the global SGNDV-003 retrospective study. Poster presentation. Abstract 4562. May 31, 2026; 9 a.m.-12 p.m.
ETCTN 10302: A randomized phase II trial of radium-223 dichloride in combination with paclitaxel in patients with bone metastatic breast cancer. Poster Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology. Abstract 3096. Poster Board 233. May 30, 2026; 1:30-4:30 p.m.
Neuropsychiatric symptom and biomarker changes with electroacupuncture in adolescent and young adult cancer survivors: Results from a randomized controlled trial. Poster Session: Pediatric Oncology. Abstract 10054. Poster Board 305. June 1, 2026; 1:30-4:30 p.m.
Phase 2 study of metronomic cyclophosphamide with pembrolizumab in checkpoint inhibitor-refractory melanoma. Poster Session: Melanoma/Skin Cancers. Abstract TPS9599. Poster Board 481b. May 31, 2026; 9 a.m.-12 p.m.
To schedule a meeting at ASCO, contact UCI Health senior manager of business development, Ken Salehi, by phone at 310-709-0108 or email salehk@hs.uci.edu
Connect With Us
UCI Health Physicians on LinkedIn